Clinical Trials11 Nov 2021 11:58
Keeping this statement in mind:-
“We remain on track to have our two lead products fully tested by the end of the year and look forward to reporting the data in Q1 2022.”
Makes me wonder if this tweet from yesterday is significant :-
“Verici Dx
@VericiDx
While kidney transplants are routine, a patient's individual immune response and other related biological pathways are, at best, an educated guess…
Until now.
Our proprietary tests forecast which patients are most at risk of rejection, to take early action.”